Novel Lipid Mediators as a Promising Therapeutic Strategy for Ischemic Stroke

Area of Science:

• Neuroscience
• Pharmacology
• Biomedical Engineering

Background:

• Neuroprotection strategies have largely failed in clinical stroke trials due to translational difficulties between preclinical and clinical studies.
• Ischemic stroke pathophysiology is complex, necessitating multifaceted therapeutic approaches.
• Combinatorial therapies targeting both inflammation and cell survival are emerging as promising strategies.

Purpose of the Study:

• To test the hypothesis that combined blockade of platelet-activating factor receptor (PAF-R) with LAU-0901 and administration of neuroprotectin D1 (AT-NPD1) enhances neurological recovery after ischemic stroke.
• To evaluate the efficacy and therapeutic window of this combinatorial therapy in a middle cerebral artery occlusion (MCAo) model.

Main Methods:

• Middle cerebral artery occlusion (MCAo) model in rodents to induce ischemic stroke.
• Treatment with LAU-0901 (PAF-R antagonist) and AT-NPD1 (docosanoid activating cell-survival pathways), both alone and in combination.
• Assessment of neuroprotection and neurological recovery at various time points post-stroke, including a 6-hour therapeutic window.

Main Results:

• The combination of LAU-0901 and AT-NPD1 provided significant neuroprotection in the MCAo model.
• The combined treatment was equally or more effective than either agent alone, even at moderate doses.
• A broad therapeutic window was observed, with benefits extending up to 6 hours after stroke onset.

Conclusions:

• Combined blockade of PAF-R with LAU-0901 and administration of AT-NPD1 represents a highly effective neuroprotective strategy for ischemic stroke.
• This combinatorial approach warrants further investigation for clinical translation in stroke patients.
• The findings highlight the potential of targeting both pro-inflammatory and pro-survival pathways for stroke treatment.